NY-ALKEGEN
8.6.2022 19:52:05 CEST | Business Wire | Press release
Alkegen, a leading specialty materials platform creating transformational battery materials, today announced they will be exhibiting at the upcoming AABC Europe Conference in Mainz, and The Battery Show Europe in Stuttgart, Germany. Alkegen’s Battery Group focuses on delivering battery innovation with advanced materials for Lithium Ion Battery (LiB) thermal barriers and electrical protection, battery separator technology, and revolutionary silicon fiber anode battery material (SiFAB®) that enables greater energy density, faster charges, and longer battery life in electric vehicles, portable electronics and energy storage systems. Alkegen, formerly Unifrax and Lydall, is a one-of-a-kind specialty materials platform dedicated to human health and sustainability.
The technical capabilities of the Alkegen Battery Group support customer partnerships with a global engineering team, deep technical expertise, and customer collaboration. These unique capabilities allow for a globally coordinated team of engineers and designers with a dedicated presence in each region, solutions designed for easy installation and handling, and scalable, customized solutions that meet budgets and optimize performance.
Alkegen’s range of technical capabilities includes Design, Testing, Prototyping and Serial Production. The global design team employs 3D modelling software to collaborate with customers and optimize form, fit and function. Thermal, mechanical, environmental and compression testing are used for part validation and new product development. The engineering team prototypes both in-pack and in-cell solutions once designed to validate product functionality. Finally, Alkegen’s global footprint of IATF certified sites and engineering teams support scale up through regional production locations in Europe, North America and the Asia-Pacific region.
Alkegen’s transformational battery portfolio includes both in-cell and in-pack solutions. In-cell solutions such as separators and additives to improve cell performance and safety include SiFAB, Alkegen’s fibrous silicon anode battery material with ultra-high capacity that enables greater energy density and is highly scalable. SiFAB technology was launched last year and will scale to production this summer. Also from Alkegen, Inovion™ is a high surface area fibrous separator paper that promotes rapid ion exchange. Alkegen also offers several in-pack solutions including high-temperature lightweight products designed to reduce thermal runaway propagation along with providing mechanical, electrical and thermal protections within the battery pack. Innovative product solutions also include FyreBlocker™ LiB, AlkeGel™ Aerogel Materials and FyreWrap® LiB performance materials. These in-cell and in-pack innovations have valuable functions in numerous industries and applications from portable electronics, e-mobility, to robotics.
”Alkegen’s Battery Group is focused on delivering the latest battery technologies and developments from our long-standing tradition of innovating unique material technologies to create superior new products and solutions for our customers’ greatest challenges,” explained Adam Kelsall, General Manager, Alkegen Battery Group. “This transformational portfolio presents numerous opportunities for Alkegen with applications spanning EV lithium-ion battery fire protection, creating greater battery energy density and delivering longer battery life in both electric vehicles and consumer electronics,” said Kelsall.
Alkegen will be available to discuss these innovative new battery materials and more during the 2022 AABC Europe Show June 13-15, in Mainz, and The Battery Show June 28-30, in Stuttgart, Germany. Interested attendees can sign up for sessions with our Alkegen Battery Group experts to meet during the conferences by contacting us at info@alkegen.com .
About Alkegen
Alkegen, formerly Unifrax and Lydall Materials, creates high performance specialty materials used in advanced applications including electric vehicles, energy storage, filtration, fire protection and high-temperature insulation, among many others. Alkegen is vertically integrated across multiple process technology platforms designed with the ultimate goal of saving energy, reducing pollution, and improving safety for people, buildings and equipment by delivering on our mission of helping the world breathe easier, live greener and go further than ever before. Alkegen has 75 manufacturing facilities operating in 12 countries and employs 9,000+ employees globally. More information is available at www.alkegen.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220608006046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom